{"gene":"CDKN2C","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":1994,"finding":"CDKN2C/p18(INK4c) directly binds CDK6 (strongly) and CDK4 (weakly) in vivo and in vitro, forms binary complexes (not ternary with cyclins), inhibits cyclin D-CDK6 kinase activity, and suppresses cell growth in a pRb-dependent manner.","method":"Yeast two-hybrid screen, co-immunoprecipitation, in vitro kinase assay, ectopic expression with growth suppression assay","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro kinase assay + Co-IP + functional growth suppression, replicated across multiple labs","pmids":["8001816"],"is_preprint":false},{"year":1995,"finding":"Mouse p18(INK4c) specifically inhibits CDK4 and CDK6 kinase activities but not cyclin E-CDK2, cyclin A-CDK2, or cyclin B-CDC2; it binds CDK4/6 whether free or in cyclin D complexes, displaces cyclins from CDKs in vivo (forming binary inhibitor-CDK complexes), and ectopic expression causes G1 arrest.","method":"In vitro kinase assays, co-immunoprecipitation, ectopic expression with FACS cell cycle analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro reconstitution + in vivo complex analysis + G1 arrest phenotype, replicated","pmids":["7739547"],"is_preprint":false},{"year":1997,"finding":"In terminally differentiating B cells, IL-6 activates p18(INK4c) expression, markedly enhances its association with CDK6, suppresses pRb phosphorylation, and causes cell cycle arrest; overexpression of p18 in IgM-bearing lymphoblastoid cells reconstitutes coupled differentiation and cell cycle arrest.","method":"Co-immunoprecipitation, Western blot, ectopic overexpression, flow cytometry","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP + overexpression rescue + defined cellular phenotype","pmids":["9052836"],"is_preprint":false},{"year":1998,"finding":"p18(INK4c)-deficient mice develop gigantism, organomegaly, pituitary hyperplasia progressing to adenoma; combined loss of p18 and p27 (two distinct CDK inhibitor pathways) leads to invariable pituitary adenoma death by 3 months, demonstrating that p18 and p27 suppress pituitary tumorigenesis via separate pathways converging on Rb.","method":"Gene targeting (knockout mice), histopathology, epistasis with p27 double knockout","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 — clean KO with defined phenotype + genetic epistasis replicated in multiple genotypes","pmids":["9744866"],"is_preprint":false},{"year":1999,"finding":"NMR and H/D exchange analyses show that p18(INK4c) is more kinetically stable than p16(INK4A) and p15(INK4B), with slowly exchanging residues concentrated in the fourth ankyrin repeat, conferring distinct conformational flexibility on the microsecond–hour timescale.","method":"NMR (heteronuclear NOE, H/D exchange), chemical denaturation","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 — NMR structural characterization with functional stability comparison","pmids":["10556039"],"is_preprint":false},{"year":1999,"finding":"During adipogenesis, PPARγ directly induces p18(INK4c) expression at the onset of terminal differentiation, coordinating irreversible G1 arrest; ectopic PPARγ in non-precursor fibroblasts induces p18 mRNA and protein in a ligand-dependent manner.","method":"Stable cell lines with ectopic PPARγ, Western blot, Northern blot, PPARγ ligand treatment","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 — ectopic transcription factor expression with defined p18 induction and differentiation phenotype","pmids":["10358062"],"is_preprint":false},{"year":2000,"finding":"Ablation of p18(INK4c) alone or combined with p15(INK4b) causes lymphoproliferative disorders and renal/mammary epithelial cysts in mice; p15 but not p18 loss confers proliferative advantage to MEFs and sensitizes them to H-ras transformation, indicating non-redundant tumor suppressor roles in different lineages.","method":"Gene targeting (single and double knockout mice), MEF transformation assays, histopathology","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 2 — clean KO with defined phenotype + double KO epistasis","pmids":["10880462"],"is_preprint":false},{"year":2000,"finding":"Progestin treatment of T-47D breast cancer cells increases p18(INK4c) expression and promotes its extensive association with CDK4 and CDK6; recombinant p18(INK4c) in vitro reassorts cyclin-CDK-inhibitor complexes, indirectly reducing cyclin E-CDK2 activity, demonstrating cooperation with p27(Kip1) in G1 arrest.","method":"Co-immunoprecipitation, in vitro kinase assay with recombinant p18, Western blot, gel filtration","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro reconstitution + in vivo Co-IP with defined functional consequence","pmids":["10713180"],"is_preprint":false},{"year":2001,"finding":"p18(INK4c) is required for B cell terminal differentiation into functional plasma cells: p18-null B cells hyperproliferate in germinal centers and extrafollicular foci but produce severely reduced antibody titers, linking p18-mediated CDK6 inhibition to cell cycle exit required for plasma cell function.","method":"Knockout mice, B cell immunization assays, antibody titer measurement, histology","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 — clean KO with defined cellular and immunological phenotype","pmids":["12196289"],"is_preprint":false},{"year":2001,"finding":"p18(INK4c) selectively associates with and inhibits CDK6 (not CDK4) in activated T cells; p18-null T cells hyperproliferate in response to CD3 stimulation, and p18 sets an inhibitory threshold on TCR-mediated proliferation via CDK6.","method":"Knockout mice, co-immunoprecipitation, T cell proliferation assays, flow cytometry","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — KO phenotype + selective Co-IP with CDK6","pmids":["11544316"],"is_preprint":false},{"year":2001,"finding":"Combined loss of Ink4c and Ink4d in mice causes male infertility through delayed spermatogonial exit from mitosis, aberrant meiosis, spermatocyte apoptosis, and Leydig cell hyperplasia with reduced testosterone; Ink4c single loss causes Leydig cell hyperplasia independently of Ink4d.","method":"Single and double knockout mice, histopathology, hormone measurements, cell cycle analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — clean double KO with defined spermatogenesis and endocrine phenotype","pmids":["11287627"],"is_preprint":false},{"year":2002,"finding":"p18(INK4c) is overexpressed in multiple myeloma (MM) cell lines with p16 co-deletion; zinc-inducible ectopic p18 expression in p18-deficient MM cells causes 40–45% growth suppression and induces apoptosis, demonstrating that p18 inhibits the cyclin D1/CDK/pRb pathway in myeloma.","method":"Inducible expression system, trypan blue exclusion, MTS assay, apoptosis assay","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 — clean inducible OE with defined apoptosis and growth phenotype, single lab","pmids":["11840272"],"is_preprint":false},{"year":2002,"finding":"Posttranscriptional upregulation of p18(INK4c) protein during oligodendrocyte precursor cell (OPC) proliferation contributes to a cell-intrinsic differentiation timer; overexpression of p18 in OPCs accelerates premature differentiation.","method":"Overexpression in primary OPC cultures, cell cycle analysis, differentiation assay","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2–3 — overexpression phenotype in primary cells, single lab","pmids":["11969268"],"is_preprint":false},{"year":2003,"finding":"Haploinsufficiency of p18(INK4c) in mice sensitizes to carcinogen-induced tumorigenesis; the remaining wild-type allele is neither mutated nor silenced in heterozygote tumors, establishing p18 as a haploinsufficient tumor suppressor.","method":"Chemical carcinogenesis in p18+/- and p18-/- mice, LOH analysis, sequencing","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic model with molecular verification of haploinsufficiency","pmids":["12556487"],"is_preprint":false},{"year":2005,"finding":"Ink4c (p18) collaborates with p53 independently of Patched to suppress medulloblastoma: Ink4c haploinsufficiency combined with Ptc1 heterozygosity causes rapid medulloblastoma with loss of the wild-type Ptc1 allele (not Ink4c), showing Ink4c haploinsufficiency for tumor suppression in this context.","method":"Mouse genetics (compound heterozygous/null crosses), LOH analysis, GNP cell proliferation assays, in situ hybridization","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis in vivo + LOH molecular analysis + cell culture phenotype","pmids":["16260494"],"is_preprint":false},{"year":2005,"finding":"Deletion of p18(INK4c) in hematopoietic stem cells (HSCs) results in improved long-term engraftment and increased self-renewing divisions; p18 absence significantly decelerates hematopoietic exhaustion caused by p21 deficiency, demonstrating opposing roles of p18 (restricts self-renewal) and p21 (limits exhaustion) at the HSC level.","method":"Serial bone marrow transplantation, single KO and double KO mice, competitive repopulation assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — clean KO with defined HSC functional phenotype across multiple transplant generations","pmids":["16234365"],"is_preprint":false},{"year":2006,"finding":"p18(INK4c) cooperates with p27(Kip1) to suppress MEN-like pituitary and thyroid tumorigenesis; oncogenic RET2A represses p18 mRNA levels via MAPK signaling, reduces p18 protein, elevates cyclin D1, increases CDK activity and pRb phosphorylation, and p18 downregulation is required and sufficient for RET2A-mediated mitogenesis.","method":"Inducible RET2A expression, RT-PCR, Western blot, kinase assay, antisense knockdown, double KO mice","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (knockdown, KO mice, kinase assay) in single lab","pmids":["16953232"],"is_preprint":false},{"year":2006,"finding":"p18 Ink4c and Pten cooperate to suppress tumorigenesis via a positive feedback loop between cell growth (PI3K/Akt/mTOR) and cell cycle control; p18 deletion, CDK4 overexpression, or viral Rb inactivation each cause Akt activation, suggesting the CDK4-Rb pathway feeds back to regulate Akt.","method":"Double mutant mice (p18/Pten), Western blot for Akt activation, tumor incidence analysis","journal":"Molecular and cellular biology","confidence":"Medium","confidence_rationale":"Tier 2 — genetic epistasis in vivo + biochemical readout, single lab","pmids":["16738322"],"is_preprint":false},{"year":2008,"finding":"Crystal structure of AIMP3/p18 (a component of the multi-tRNA synthetase complex, also known as p18 tumor suppressor) determined at 2.0 Å; structure reveals two distinct domains; mutations at the C-terminal domain abolish interaction with ATM and p53 activation, identifying residues critical for tumor-suppressive activity.","method":"X-ray crystallography, mutagenesis, co-immunoprecipitation, p53 activation assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — crystal structure + mutagenesis + functional validation in single study","pmids":["18343821"],"is_preprint":false},{"year":2008,"finding":"Somatic mutations in CDKN2C/p18(INK4c) found in human RET-associated medullary thyroid carcinoma and pheochromocytoma cause amino acid substitutions in the CDK-interacting region, partially inhibit p18 function and reduce its stability, implicating p18 as a tumor suppressor in these cancers.","method":"Mutation sequencing of patient tumors, in vitro functional assays of mutant p18","journal":"International journal of cancer","confidence":"Medium","confidence_rationale":"Tier 2 — somatic mutations + in vitro functional characterization, single lab","pmids":["18942719"],"is_preprint":false},{"year":2008,"finding":"Lentiviral reconstitution of p18(INK4c) expression at physiological levels in p18-deficient GBM cells induces senescence-like G1 arrest; p18-proficient GBM cells are unaffected, identifying p18 loss as a driver of CDK dysregulation in glioblastoma.","method":"Lentiviral gene reconstitution, flow cytometry (cell cycle), immunohistochemistry","journal":"Cancer research","confidence":"Medium","confidence_rationale":"Tier 2 — clean reconstitution experiment with defined G1 arrest phenotype, single lab","pmids":["18381405"],"is_preprint":false},{"year":2009,"finding":"GATA3 directly binds the INK4C/CDKN2C promoter and represses its transcription, placing p18(INK4c) downstream of GATA3 in luminal mammary progenitor cells; p18-null mice spontaneously develop ER-positive luminal tumors with expanded luminal progenitor populations.","method":"ChIP, luciferase reporter assay, knockout mice, tumor histopathology, gene expression profiling","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 1–2 — ChIP + reporter assay + KO phenotype, multiple orthogonal methods","pmids":["19411068"],"is_preprint":false},{"year":2010,"finding":"AIMP3/p18 overexpression causes proteasome-dependent degradation of mature lamin A (not lamin C, prelamin A, or progerin), leading to altered lamin A isoform stoichiometry, accelerated cellular senescence, nuclear morphology defects, and a progeroid phenotype in transgenic mice.","method":"Transgenic mice, Western blot, proteasome inhibitor treatment, cell morphology assay","journal":"Aging cell","confidence":"Medium","confidence_rationale":"Tier 2 — transgenic OE + proteasome inhibitor rescue + defined phenotype, single lab","pmids":["20726853"],"is_preprint":false},{"year":2011,"finding":"Cdkn2c/p18 deficiency in C57BL/6 mice causes dose-dependent expansion of peritoneal B1a cells (but not splenic conventional B cells) with enhanced homeostatic B1a proliferation; elevated B1a numbers are normalized by cyclin D2 deficiency, placing p18 upstream of cyclin D2 in B1a cell pool regulation.","method":"Knockout mice, flow cytometry, cyclin D2 double KO epistasis, autoantibody measurement","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 — clean KO + epistasis with cyclin D2 + defined cellular phenotype","pmids":["22896639"],"is_preprint":false},{"year":2012,"finding":"MAPK/BRAF(V600E) signaling promotes melanoma G1 cell cycle progression via AP-1-mediated transcriptional repression of CDKN2C; dominant-negative AP-1 de-represses CDKN2C, and CDK4 inhibition antagonizes BRAF(V600E) proliferative effects.","method":"Dominant-negative AP-1, cell proliferation assay, Western blot, flow cytometry, in vivo xenograft","journal":"Journal of the National Cancer Institute","confidence":"Medium","confidence_rationale":"Tier 2 — dominant-negative + pharmacological inhibition + in vivo validation, single lab","pmids":["22997239"],"is_preprint":false},{"year":2013,"finding":"GATA3 associates with RuvBL2 (Ruvbl2) to form a complex that directly binds the Cdkn2c locus and represses Cdkn2c expression in Th2 cells; knockdown of Cdkn2c rescues the proliferation defect of Gata3-deficient Th2 cells, establishing Cdkn2c as a key mediator of Gata3-driven Th2 cell proliferation.","method":"ChIP, co-immunoprecipitation, siRNA knockdown, in vitro proliferation assay, in vivo airway inflammation model","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 — ChIP + Co-IP + knockdown rescue, multiple orthogonal methods","pmids":["24167278"],"is_preprint":false},{"year":2015,"finding":"Small-molecule inhibitors identified by structure-based in silico screening against p18(INK4c) specifically block p18 activity and expand functional HSCs in short-term culture, demonstrating that pharmacological inhibition of p18's CDK-inhibitory function promotes HSC self-renewing division.","method":"In silico screening based on p18 protein structure, in vitro kinase inhibition assay, single-cell HSC culture, transplantation assay","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 — structure-guided inhibitor design + functional HSC expansion assay, single lab","pmids":["25692908"],"is_preprint":false},{"year":2018,"finding":"SETDB2 (protein lysine methyltransferase) suppresses CDKN2C expression via histone H3K9 tri-methylation at the CDKN2C locus downstream of the E2A-PBX1 chimeric transcription factor in pre-BCR+ ALL, establishing an oncogenic pathway that silences CDKN2C as a major tumor suppressor.","method":"ChIP, SETDB2 knockdown, gene expression analysis, in vitro and in vivo leukemia maintenance assays","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — ChIP + KD with defined phenotype + epistatic pathway placement","pmids":["29694893"],"is_preprint":false},{"year":2020,"finding":"miR-21-5p directly targets CDKN2C 3'UTR (validated by luciferase reporter assay), decreases CDKN2C protein levels, and promotes G1/S transition and proliferation in melanoma cells; CDKN2C overexpression partially reverses miR-21-5p-driven proliferation.","method":"Luciferase reporter assay, miRNA mimic/inhibitor, Western blot, flow cytometry, rescue experiment","journal":"FEBS open bio","confidence":"Medium","confidence_rationale":"Tier 2 — direct 3'UTR reporter validation + rescue experiment, single lab","pmids":["32090490"],"is_preprint":false},{"year":2020,"finding":"PRMT6 epigenetically suppresses CDKN2C/p18 expression via asymmetric dimethylation of histone H3R2 at the p18 promoter; PRMT6 knockdown reduces H3R2me2a enrichment at the p18 promoter, activates p18 expression, induces G1/S arrest, and inhibits lung adenocarcinoma cell proliferation in vitro and in vivo.","method":"ChIP assay, PRMT6 siRNA knockdown, Western blot, cell cycle analysis, xenograft model","journal":"Molecular medicine reports","confidence":"Medium","confidence_rationale":"Tier 2 — ChIP + KD + in vivo validation, single lab","pmids":["32945431"],"is_preprint":false},{"year":1996,"finding":"p18(INK4c) and p16(INK4A) each form 1:1 binary complexes with CDK4/CDK6 (no free kinase detectable); p16 can dissociate preformed CDK4-cyclin D1 complexes in vitro, demonstrating competitive displacement of cyclin by INK4 inhibitors.","method":"In vitro dissociation assay with purified proteins, co-immunoprecipitation, Western blot","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution demonstrating competitive displacement with purified components","pmids":["8663131"],"is_preprint":false},{"year":2014,"finding":"miR-543 and miR-590-3p directly bind AIMP3/p18 transcripts and decrease AIMP3/p18 expression; their levels decline under senescence-inducing conditions in human MSCs, allowing AIMP3/p18 upregulation which induces senescence phenotypes including impaired clonogenicity and adipogenic differentiation.","method":"miRNA mimic/inhibitor transfection, luciferase reporter assay (direct binding), Western blot, senescence assays","journal":"Age (Dordrecht, Netherlands)","confidence":"Medium","confidence_rationale":"Tier 2 — direct binding validated by reporter + loss-of-function phenotype, single lab","pmids":["25465621"],"is_preprint":false}],"current_model":"CDKN2C/p18(INK4c) is a CDK inhibitor that forms binary complexes with CDK4 and CDK6 (preferentially CDK6), competitively displacing D-type cyclins to block G1-phase kinase activity and pRb phosphorylation, thereby restraining cell cycle entry; its expression is transcriptionally repressed by GATA3/RuvBL2 and AP-1 downstream of BRAF(V600E)/MAPK signaling, epigenetically silenced by SETDB2 (H3K9me3) and PRMT6 (H3R2me2a), and post-transcriptionally regulated by miR-21-5p and miR-543/590-3p, while loss of p18 collaborates with loss of p27 and inactivation of p53 or Pten to promote tissue-specific tumorigenesis (pituitary, mammary, thyroid, hematopoietic), and p18 also restricts hematopoietic stem cell self-renewal and controls terminal differentiation in B cells, T cells, and spermatocytes."},"narrative":{"teleology":[{"year":1994,"claim":"Identification of p18(INK4c) as a CDK6/CDK4-specific inhibitor that forms binary (not ternary) complexes and suppresses growth in a pRb-dependent manner established the founding biochemical mechanism of this INK4 family member.","evidence":"Yeast two-hybrid, co-immunoprecipitation, in vitro kinase assays, and ectopic expression growth suppression in human cells","pmids":["8001816"],"confidence":"High","gaps":["Structural basis for CDK6 preference over CDK4 not resolved","Endogenous physiological context of p18 action unknown"]},{"year":1995,"claim":"Demonstration that p18 specifically inhibits CDK4/6 but not CDK2 or CDC2, and displaces cyclins from preformed complexes in vivo, clarified the competitive displacement mechanism and CDK selectivity of INK4c.","evidence":"In vitro kinase assays across multiple CDK-cyclin pairs, co-immunoprecipitation of endogenous complexes, FACS cell cycle analysis in mouse cells","pmids":["7739547","8663131"],"confidence":"High","gaps":["Quantitative binding affinities for CDK4 vs CDK6 not determined","Whether cyclin displacement is kinetically reversible in vivo unknown"]},{"year":1997,"claim":"Discovery that IL-6 induces p18 during B cell terminal differentiation, coupling CDK6 inhibition to cell cycle exit and immunoglobulin secretion, provided the first physiological differentiation context for p18.","evidence":"Co-immunoprecipitation showing enhanced p18-CDK6 association, overexpression reconstituting coupled differentiation and arrest in lymphoblastoid cells","pmids":["9052836"],"confidence":"High","gaps":["Transcriptional vs post-transcriptional regulation by IL-6 not dissected","Whether p18 is required (vs sufficient) for plasma cell differentiation not tested"]},{"year":1998,"claim":"Knockout mouse studies established p18 as a bona fide tumor suppressor whose loss causes pituitary hyperplasia/adenoma and cooperates with p27 loss through independent pathways converging on Rb, defining the in vivo tumor suppressor function.","evidence":"Gene targeting in mice with single and double (p18/p27) knockouts, histopathology, epistasis analysis","pmids":["9744866"],"confidence":"High","gaps":["Cell-autonomous vs systemic (e.g. hormonal) contribution to pituitary tumorigenesis not separated","Human pituitary tumor relevance not established"]},{"year":1999,"claim":"NMR structural analysis revealed that p18 has greater kinetic stability than p16 and p15, with the fourth ankyrin repeat as the stability core, providing a biophysical basis for differential INK4 family behavior.","evidence":"NMR heteronuclear NOE and H/D exchange measurements, chemical denaturation comparison","pmids":["10556039"],"confidence":"High","gaps":["No co-crystal structure with CDK6 to map the binding interface","Functional consequence of enhanced stability not tested in cells"]},{"year":1999,"claim":"Identification of PPARγ as a direct transcriptional activator of p18 during adipogenesis linked p18 induction to the irreversible cell cycle exit accompanying terminal differentiation in a non-hematopoietic lineage.","evidence":"Ectopic PPARγ expression in fibroblasts with ligand-dependent p18 mRNA/protein induction","pmids":["10358062"],"confidence":"High","gaps":["Direct promoter binding by PPARγ not shown by ChIP","Whether p18 is necessary for adipocyte cell cycle exit not tested by loss-of-function"]},{"year":2000,"claim":"Studies in breast cancer cells showed that progestin-induced p18 upregulation reassorts CDK-cyclin-inhibitor complexes to indirectly suppress cyclin E-CDK2 activity through cooperation with p27, revealing a two-step CDK inhibition cascade linking INK4 and Cip/Kip families.","evidence":"Co-immunoprecipitation, in vitro reconstitution with recombinant p18, gel filtration of endogenous complexes","pmids":["10713180"],"confidence":"High","gaps":["Stoichiometric requirements for complex reassortment not quantified","In vivo relevance of progestin-p18 axis in mammary tumor suppression not tested"]},{"year":2001,"claim":"Functional studies in knockout mice extended p18's differentiation roles to T cells (CDK6-selective threshold on TCR proliferation), B cell plasma cell differentiation (required for antibody production), and spermatogenesis (cooperation with p19/INK4d for meiotic progression), demonstrating broad lineage-specific functions.","evidence":"Single and double knockout mice with immunization, proliferation assays, histopathology, and hormone measurements","pmids":["11544316","12196289","11287627"],"confidence":"High","gaps":["Whether CDK6 selectivity in T cells reflects expression patterns or intrinsic affinity not resolved","Molecular mechanism linking p18 loss to meiotic defects unknown"]},{"year":2003,"claim":"Demonstration that p18 is haploinsufficient for tumor suppression — heterozygous mice develop carcinogen-induced tumors without loss or silencing of the remaining allele — established a dosage-sensitive mode of tumor suppression distinct from classical two-hit models.","evidence":"Chemical carcinogenesis in p18+/- mice with LOH analysis and sequencing of remaining allele","pmids":["12556487"],"confidence":"High","gaps":["Whether haploinsufficiency operates in human cancers not tested","Threshold level of p18 protein required for tumor suppression unknown"]},{"year":2005,"claim":"Discovery that p18 restricts hematopoietic stem cell self-renewal, with p18 loss improving long-term engraftment and opposing the exhaustion phenotype of p21 deficiency, positioned p18 as a stem cell quiescence regulator distinct from proliferation arrest.","evidence":"Serial competitive bone marrow transplantation in single and double knockout mice","pmids":["16234365"],"confidence":"High","gaps":["Whether p18 acts cell-autonomously in HSCs vs through niche effects not fully resolved","CDK4 vs CDK6 target in HSCs not determined"]},{"year":2006,"claim":"Genetic epistasis between p18/Pten and p18/p27 in thyroid and pituitary tumorigenesis revealed crosstalk between CDK4-Rb and PI3K/Akt/mTOR pathways, with p18 deletion activating Akt, suggesting a feedback loop from cell cycle control to growth signaling.","evidence":"Compound mutant mice, Western blot for Akt phosphorylation, tumor incidence and histopathology","pmids":["16738322","16953232"],"confidence":"Medium","gaps":["Mechanism of CDK4-Rb to Akt feedback not molecularly defined","Whether feedback operates in human tumors unknown"]},{"year":2009,"claim":"ChIP and reporter assays showed GATA3 directly binds and represses the CDKN2C promoter in mammary and Th2 cells (via a RuvBL2-containing complex), and p18-null mice develop ER-positive luminal tumors, establishing a GATA3→p18 transcriptional axis controlling luminal progenitor expansion.","evidence":"ChIP, luciferase reporter, co-immunoprecipitation of GATA3-RuvBL2, knockout mice with tumor histopathology, siRNA rescue","pmids":["19411068","24167278"],"confidence":"High","gaps":["Whether GATA3 mutations in human breast cancer act through p18 derepression not tested","Genomic occupancy of GATA3-RuvBL2 at CDKN2C not mapped at nucleotide resolution"]},{"year":2012,"claim":"Identification of AP-1-mediated CDKN2C transcriptional repression downstream of BRAF(V600E)/MAPK signaling in melanoma explained how oncogenic MAPK activity overrides the p18-CDK4/6-Rb checkpoint.","evidence":"Dominant-negative AP-1 derepresses CDKN2C, CDK4 inhibitor blocks BRAF(V600E) proliferative effects in vitro and xenograft","pmids":["22997239"],"confidence":"Medium","gaps":["Direct AP-1 binding to CDKN2C promoter not confirmed by ChIP","Relative contribution of p18 vs p16 repression in melanoma not quantified"]},{"year":2015,"claim":"Structure-based small-molecule inhibitors of p18 expanded functional HSCs in culture and transplantation, providing pharmacological proof-of-concept that p18's CDK-inhibitory activity can be therapeutically targeted to enhance stem cell self-renewal.","evidence":"In silico screening against p18 structure, in vitro kinase assay, single-cell HSC culture, transplantation","pmids":["25692908"],"confidence":"Medium","gaps":["Selectivity of inhibitors for p18 over other INK4 members not fully characterized","Long-term safety of p18 inhibition in vivo not assessed"]},{"year":2018,"claim":"Discovery that SETDB2 deposits H3K9me3 at the CDKN2C locus downstream of the E2A-PBX1 oncofusion to silence p18 in pre-B ALL established an epigenetic silencing axis as a tumor maintenance mechanism.","evidence":"ChIP for H3K9me3, SETDB2 knockdown restoring CDKN2C expression, in vivo leukemia maintenance assay","pmids":["29694893"],"confidence":"High","gaps":["Whether H3K9me3-based silencing is reversible with epigenetic drugs not tested","Other SETDB2 targets that may contribute to leukemia maintenance not excluded"]},{"year":2020,"claim":"Identification of miR-21-5p and PRMT6 (H3R2me2a) as additional negative regulators of CDKN2C in melanoma and lung adenocarcinoma, respectively, expanded the repertoire of post-transcriptional and epigenetic mechanisms that silence p18 in cancer.","evidence":"Luciferase 3'UTR reporter for miR-21-5p, ChIP for H3R2me2a at p18 promoter with PRMT6 knockdown, xenograft validation","pmids":["32090490","32945431"],"confidence":"Medium","gaps":["Relative quantitative contribution of each silencing mechanism in individual tumors unknown","Whether PRMT6 and SETDB2 act on the same or distinct chromatin states at CDKN2C not determined"]},{"year":null,"claim":"Key unresolved questions include the high-resolution structural basis for p18's strong CDK6 preference over CDK4, whether the CDK4-Rb-to-Akt feedback loop is a general mechanism in human cancers, and the therapeutic window for pharmacological p18 inhibition in stem cell expansion without tumor risk.","evidence":"","pmids":[],"confidence":"Low","gaps":["No co-crystal structure of p18-CDK6 complex available","Mechanism of CDK4-Rb to Akt feedback not molecularly defined","Long-term oncogenic risk of p18 inhibition in HSC expansion not assessed"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[0,1,7,30]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[20,29]}],"pathway":[{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[0,1,7,30]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[3,13,14,19,27]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[16,17,24]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[5,8,10,12]}],"complexes":[],"partners":["CDK6","CDK4","GATA3","RUVBL2","SETDB2","PRMT6"],"other_free_text":[]},"mechanistic_narrative":"CDKN2C/p18(INK4c) is a CDK inhibitor that restrains G1-phase cell cycle progression by forming binary complexes with CDK4 and especially CDK6, competitively displacing D-type cyclins to block pRb phosphorylation and enforce cell cycle exit during terminal differentiation in B cells, T cells, adipocytes, oligodendrocyte precursors, and spermatocytes [PMID:8001816, PMID:7739547, PMID:9052836, PMID:10358062]. p18 functions as a haploinsufficient tumor suppressor whose loss cooperates with deficiency of p27(Kip1), p53, or Pten to drive pituitary, thyroid, mammary, and hematopoietic tumors in mice, and whose expression is transcriptionally repressed by GATA3/RuvBL2, AP-1 downstream of BRAF(V600E)/MAPK signaling, and epigenetically silenced by SETDB2-mediated H3K9me3 and PRMT6-mediated H3R2me2a [PMID:9744866, PMID:12556487, PMID:19411068, PMID:29694893, PMID:32945431]. In the hematopoietic stem cell compartment, p18 restricts self-renewal such that its genetic or pharmacological inhibition expands functional HSCs [PMID:16234365, PMID:25692908]. Somatic loss-of-function mutations in CDKN2C occur in RET-associated medullary thyroid carcinoma and pheochromocytoma, and CDKN2C silencing contributes to glioblastoma and melanoma progression [PMID:18942719, PMID:18381405, PMID:22997239]."},"prefetch_data":{"uniprot":{"accession":"P42773","full_name":"Cyclin-dependent kinase 4 inhibitor C","aliases":["Cyclin-dependent kinase 6 inhibitor","p18-INK4c","p18-INK6"],"length_aa":168,"mass_kda":18.1,"function":"Interacts strongly with CDK6, weakly with CDK4. Inhibits cell growth and proliferation with a correlated dependence on endogenous retinoblastoma protein RB","subcellular_location":"","url":"https://www.uniprot.org/uniprotkb/P42773/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CDKN2C","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"CDK4","stoichiometry":10.0}],"url":"https://opencell.sf.czbiohub.org/search/CDKN2C","total_profiled":1310},"omim":[{"mim_id":"603369","title":"CYCLIN-DEPENDENT KINASE INHIBITOR 2C; CDKN2C","url":"https://www.omim.org/entry/603369"},{"mim_id":"600927","title":"CYCLIN-DEPENDENT KINASE INHIBITOR 2D; CDKN2D","url":"https://www.omim.org/entry/600927"},{"mim_id":"600778","title":"CYCLIN-DEPENDENT KINASE INHIBITOR 1B; CDKN1B","url":"https://www.omim.org/entry/600778"},{"mim_id":"164840","title":"MYCN PROTOONCOGENE, bHLH TRANSCRIPTION FACTOR; MYCN","url":"https://www.omim.org/entry/164840"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Approved","locations":[{"location":"Nucleoplasm","reliability":"Approved"},{"location":"Cytosol","reliability":"Approved"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"adipose tissue","ntpm":92.4},{"tissue":"lymphoid tissue","ntpm":89.5}],"url":"https://www.proteinatlas.org/search/CDKN2C"},"hgnc":{"alias_symbol":["INK4C","p18"],"prev_symbol":[]},"alphafold":{"accession":"P42773","domains":[{"cath_id":"1.25.40.20","chopping":"1-62","consensus_level":"medium","plddt":91.7894,"start":1,"end":62},{"cath_id":"1.25.40.20","chopping":"67-163","consensus_level":"medium","plddt":94.8254,"start":67,"end":163}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P42773","model_url":"https://alphafold.ebi.ac.uk/files/AF-P42773-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P42773-F1-predicted_aligned_error_v6.png","plddt_mean":91.88},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CDKN2C","jax_strain_url":"https://www.jax.org/strain/search?query=CDKN2C"},"sequence":{"accession":"P42773","fasta_url":"https://rest.uniprot.org/uniprotkb/P42773.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P42773/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P42773"}},"corpus_meta":[{"pmid":"8001816","id":"PMC_8001816","title":"Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function.","date":"1994","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/8001816","citation_count":765,"is_preprint":false},{"pmid":"7739547","id":"PMC_7739547","title":"Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6.","date":"1995","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7739547","citation_count":618,"is_preprint":false},{"pmid":"9639410","id":"PMC_9639410","title":"Review of alterations of the cyclin-dependent kinase inhibitor INK4 family genes p15, p16, p18 and p19 in human leukemia-lymphoma cells.","date":"1998","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/9639410","citation_count":350,"is_preprint":false},{"pmid":"9744866","id":"PMC_9744866","title":"CDK inhibitors p18(INK4c) and p27(Kip1) mediate two separate pathways to collaboratively suppress pituitary tumorigenesis.","date":"1998","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/9744866","citation_count":330,"is_preprint":false},{"pmid":"22685290","id":"PMC_22685290","title":"Elevation of highly up-regulated in liver cancer (HULC) by hepatitis B virus X protein promotes hepatoma cell proliferation via down-regulating p18.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22685290","citation_count":304,"is_preprint":false},{"pmid":"7882351","id":"PMC_7882351","title":"Mutations in the p16INK4/MTS1/CDKN2, p15INK4B/MTS2, and p18 genes in primary and metastatic lung cancer.","date":"1995","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/7882351","citation_count":271,"is_preprint":false},{"pmid":"19177150","id":"PMC_19177150","title":"The novel lipid raft adaptor p18 controls endosome dynamics by anchoring the MEK-ERK pathway to late endosomes.","date":"2009","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/19177150","citation_count":270,"is_preprint":false},{"pmid":"10358062","id":"PMC_10358062","title":"Role of PPARgamma in regulating a cascade expression of cyclin-dependent kinase inhibitors, p18(INK4c) and p21(Waf1/Cip1), during adipogenesis.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10358062","citation_count":268,"is_preprint":false},{"pmid":"10880462","id":"PMC_10880462","title":"Limited overlapping roles of P15(INK4b) and P18(INK4c) cell cycle inhibitors in proliferation and tumorigenesis.","date":"2000","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/10880462","citation_count":225,"is_preprint":false},{"pmid":"11485924","id":"PMC_11485924","title":"Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.","date":"2001","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/11485924","citation_count":219,"is_preprint":false},{"pmid":"7606004","id":"PMC_7606004","title":"Analysis of a family of cyclin-dependent kinase inhibitors: p15/MTS2/INK4B, p16/MTS1/INK4A, and p18 genes in acute lymphoblastic leukemia of childhood.","date":"1995","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/7606004","citation_count":171,"is_preprint":false},{"pmid":"21994415","id":"PMC_21994415","title":"Mapping of chromosome 1p deletions in myeloma identifies FAM46C at 1p12 and CDKN2C at 1p32.3 as being genes in regions associated with adverse survival.","date":"2011","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/21994415","citation_count":152,"is_preprint":false},{"pmid":"20507346","id":"PMC_20507346","title":"The role of germline AIP, MEN1, PRKAR1A, CDKN1B and CDKN2C mutations in causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes.","date":"2010","source":"Clinical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/20507346","citation_count":150,"is_preprint":false},{"pmid":"11343236","id":"PMC_11343236","title":"Involvement of p21(WAF1/Cip1), p27(Kip1), and p18(INK4c) in troglitazone-induced cell-cycle arrest in human hepatoma cell lines.","date":"2001","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/11343236","citation_count":148,"is_preprint":false},{"pmid":"9052836","id":"PMC_9052836","title":"Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18(INK4c) and IL-6.","date":"1997","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/9052836","citation_count":132,"is_preprint":false},{"pmid":"16260494","id":"PMC_16260494","title":"The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation.","date":"2005","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/16260494","citation_count":130,"is_preprint":false},{"pmid":"15680327","id":"PMC_15680327","title":"The haploinsufficient tumor suppressor p18 upregulates p53 via interactions with ATM/ATR.","date":"2005","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/15680327","citation_count":121,"is_preprint":false},{"pmid":"12816867","id":"PMC_12816867","title":"Cleavage of Bax to p18 Bax accelerates stress-induced apoptosis, and a cathepsin-like protease may rapidly degrade p18 Bax.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12816867","citation_count":104,"is_preprint":false},{"pmid":"16234365","id":"PMC_16234365","title":"Hematopoietic stem cell exhaustion impacted by p18 INK4C and p21 Cip1/Waf1 in opposite manners.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16234365","citation_count":102,"is_preprint":false},{"pmid":"8144611","id":"PMC_8144611","title":"Regulation of phosphoprotein p18 in leukemic cells. Cell cycle regulated phosphorylation by p34cdc2 kinase.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8144611","citation_count":100,"is_preprint":false},{"pmid":"16597877","id":"PMC_16597877","title":"Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.","date":"2006","source":"Journal of clinical microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/16597877","citation_count":96,"is_preprint":false},{"pmid":"11287627","id":"PMC_11287627","title":"Control of spermatogenesis in mice by the cyclin D-dependent kinase inhibitors p18(Ink4c) and p19(Ink4d).","date":"2001","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/11287627","citation_count":94,"is_preprint":false},{"pmid":"8603340","id":"PMC_8603340","title":"Alterations of the p15, p16,and p18 genes in osteosarcoma.","date":"1996","source":"Cancer genetics and cytogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/8603340","citation_count":92,"is_preprint":false},{"pmid":"18829482","id":"PMC_18829482","title":"Deletions of CDKN2C in multiple myeloma: biological and clinical implications.","date":"2008","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/18829482","citation_count":88,"is_preprint":false},{"pmid":"12005420","id":"PMC_12005420","title":"Antibacterial, antitumor and hemolytic activities of alpha-helical antibiotic peptide, P18 and its analogs.","date":"2001","source":"The journal of peptide research : official journal of the American Peptide Society","url":"https://pubmed.ncbi.nlm.nih.gov/12005420","citation_count":87,"is_preprint":false},{"pmid":"12196289","id":"PMC_12196289","title":"CDK inhibitor p18(INK4c) is required for the generation of functional plasma cells.","date":"2002","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/12196289","citation_count":86,"is_preprint":false},{"pmid":"11668523","id":"PMC_11668523","title":"A single nucleotide polymorphism in the 3'untranslated region of the CDKN2A gene is common in sporadic primary melanomas but mutations in the CDKN2B, CDKN2C, CDK4 and p53 genes are rare.","date":"2001","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/11668523","citation_count":84,"is_preprint":false},{"pmid":"12556487","id":"PMC_12556487","title":"Haploinsufficiency of p18(INK4c) sensitizes mice to carcinogen-induced tumorigenesis.","date":"2003","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/12556487","citation_count":83,"is_preprint":false},{"pmid":"19411068","id":"PMC_19411068","title":"CDK inhibitor p18(INK4c) is a downstream target of GATA3 and restrains mammary luminal progenitor cell proliferation and tumorigenesis.","date":"2009","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/19411068","citation_count":81,"is_preprint":false},{"pmid":"10515227","id":"PMC_10515227","title":"Identification of two distinct deleted regions on the short arm of chromosome 1 and rare mutation of the CDKN2C gene from 1p32 in oligodendroglial tumors.","date":"1999","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/10515227","citation_count":75,"is_preprint":false},{"pmid":"8849690","id":"PMC_8849690","title":"The p18 component of the multisynthetase complex shares a protein motif with the beta and gamma subunits of eukaryotic elongation factor 1.","date":"1996","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/8849690","citation_count":71,"is_preprint":false},{"pmid":"8640838","id":"PMC_8640838","title":"Antisense RNA inhibition of phosphoprotein p18 expression abrogates the transformed phenotype of leukemic cells.","date":"1996","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/8640838","citation_count":65,"is_preprint":false},{"pmid":"10713180","id":"PMC_10713180","title":"Cooperation of p27(Kip1) and p18(INK4c) in progestin-mediated cell cycle arrest in T-47D breast cancer cells.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10713180","citation_count":64,"is_preprint":false},{"pmid":"12698196","id":"PMC_12698196","title":"Antitumour effect of cyclin-dependent kinase inhibitors (p16(INK4A), p18(INK4C), p19(INK4D), p21(WAF1/CIP1) and p27(KIP1)) on malignant glioma cells.","date":"2003","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/12698196","citation_count":64,"is_preprint":false},{"pmid":"8703847","id":"PMC_8703847","title":"Analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in childhood rhabdomyosarcoma.","date":"1996","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/8703847","citation_count":63,"is_preprint":false},{"pmid":"11969268","id":"PMC_11969268","title":"Posttranscriptional regulation of p18 and p27 Cdk inhibitor proteins and the timing of oligodendrocyte differentiation.","date":"2002","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/11969268","citation_count":63,"is_preprint":false},{"pmid":"9729040","id":"PMC_9729040","title":"The crystal structure of H-2Dd MHC class I complexed with the HIV-1-derived peptide P18-I10 at 2.4 A resolution: implications for T cell and NK cell recognition.","date":"1998","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/9729040","citation_count":62,"is_preprint":false},{"pmid":"2229039","id":"PMC_2229039","title":"Amino acid sequence and characterization of a heparin-binding neurite-promoting factor (p18) from bovine brain.","date":"1990","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/2229039","citation_count":62,"is_preprint":false},{"pmid":"14500377","id":"PMC_14500377","title":"Hemangiosarcomas, medulloblastomas, and other tumors in Ink4c/p53-null mice.","date":"2003","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/14500377","citation_count":58,"is_preprint":false},{"pmid":"8631583","id":"PMC_8631583","title":"Intragenic mutations of the p16(INK4), p15(INK4B) and p18 genes in primary non-small-cell lung cancers.","date":"1996","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/8631583","citation_count":53,"is_preprint":false},{"pmid":"25465621","id":"PMC_25465621","title":"miR-543 and miR-590-3p regulate human mesenchymal stem cell aging via direct targeting of AIMP3/p18.","date":"2014","source":"Age (Dordrecht, Netherlands)","url":"https://pubmed.ncbi.nlm.nih.gov/25465621","citation_count":53,"is_preprint":false},{"pmid":"16675041","id":"PMC_16675041","title":"Characterization of the Babesia gibsoni P18 as a homologue of thrombospondin related adhesive protein.","date":"2006","source":"Molecular and biochemical parasitology","url":"https://pubmed.ncbi.nlm.nih.gov/16675041","citation_count":52,"is_preprint":false},{"pmid":"30020076","id":"PMC_30020076","title":"UBE3A-mediated p18/LAMTOR1 ubiquitination and degradation regulate mTORC1 activity and synaptic plasticity.","date":"2018","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/30020076","citation_count":50,"is_preprint":false},{"pmid":"19916573","id":"PMC_19916573","title":"In silico structural and functional analysis of fragments of the ankyrin repeat protein p18(INK4c).","date":"2010","source":"Journal of biomolecular structure & dynamics","url":"https://pubmed.ncbi.nlm.nih.gov/19916573","citation_count":49,"is_preprint":false},{"pmid":"18942719","id":"PMC_18942719","title":"P18 is a tumor suppressor gene involved in human medullary thyroid carcinoma and pheochromocytoma development.","date":"2009","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/18942719","citation_count":48,"is_preprint":false},{"pmid":"11840272","id":"PMC_11840272","title":"Frequent inactivation of the cyclin-dependent kinase inhibitor p18 by homozygous deletion in multiple myeloma cell lines: ectopic p18 expression inhibits growth and induces apoptosis.","date":"2002","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/11840272","citation_count":48,"is_preprint":false},{"pmid":"8663131","id":"PMC_8663131","title":"Biochemical characterization of p16INK4- and p18-containing complexes in human cell lines.","date":"1996","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8663131","citation_count":47,"is_preprint":false},{"pmid":"7577621","id":"PMC_7577621","title":"Structural integrity of the cyclin-dependent kinase inhibitor genes, p15, p16 and p18 in myeloid leukaemias.","date":"1995","source":"British journal of haematology","url":"https://pubmed.ncbi.nlm.nih.gov/7577621","citation_count":45,"is_preprint":false},{"pmid":"8630967","id":"PMC_8630967","title":"Molecular analysis of the cyclin-dependent kinase inhibitor family: p16(CDKN2/MTS1/INK4A), p18(INK4C) and p27(Kip1) genes in neuroblastomas.","date":"1996","source":"Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/8630967","citation_count":45,"is_preprint":false},{"pmid":"23715670","id":"PMC_23715670","title":"Germline and somatic mutations in cyclin-dependent kinase inhibitor genes CDKN1A, CDKN2B, and CDKN2C in sporadic parathyroid adenomas.","date":"2013","source":"Hormones & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/23715670","citation_count":44,"is_preprint":false},{"pmid":"25692908","id":"PMC_25692908","title":"Small-molecule inhibitors targeting INK4 protein p18(INK4C) enhance ex vivo expansion of haematopoietic stem cells.","date":"2015","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/25692908","citation_count":43,"is_preprint":false},{"pmid":"8622968","id":"PMC_8622968","title":"Complexity of the erythroid transcription factor NF-E2 as revealed by gene targeting of the mouse p18 NF-E2 locus.","date":"1996","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/8622968","citation_count":43,"is_preprint":false},{"pmid":"18381405","id":"PMC_18381405","title":"Identification of p18 INK4c as a tumor suppressor gene in glioblastoma multiforme.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18381405","citation_count":42,"is_preprint":false},{"pmid":"18973139","id":"PMC_18973139","title":"Frequent loss of the CDKN2C (p18INK4c) gene product in pituitary adenomas.","date":"2009","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/18973139","citation_count":42,"is_preprint":false},{"pmid":"9031081","id":"PMC_9031081","title":"Role of the cyclin-dependent kinase 4 and 6 inhibitor gene family p15, p16, p18 and p19 in leukemia and lymphoma.","date":"1996","source":"Leukemia & lymphoma","url":"https://pubmed.ncbi.nlm.nih.gov/9031081","citation_count":42,"is_preprint":false},{"pmid":"11544316","id":"PMC_11544316","title":"An important role of CDK inhibitor p18(INK4c) in modulating antigen receptor-mediated T cell proliferation.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11544316","citation_count":42,"is_preprint":false},{"pmid":"16738322","id":"PMC_16738322","title":"p18 Ink4c and Pten constrain a positive regulatory loop between cell growth and cell cycle control.","date":"2006","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16738322","citation_count":42,"is_preprint":false},{"pmid":"22227194","id":"PMC_22227194","title":"The late endosome/lysosome-anchored p18-mTORC1 pathway controls terminal maturation of lysosomes.","date":"2011","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/22227194","citation_count":40,"is_preprint":false},{"pmid":"20726853","id":"PMC_20726853","title":"Downregulation of lamin A by tumor suppressor AIMP3/p18 leads to a progeroid phenotype in mice.","date":"2010","source":"Aging cell","url":"https://pubmed.ncbi.nlm.nih.gov/20726853","citation_count":40,"is_preprint":false},{"pmid":"20833334","id":"PMC_20833334","title":"MEN-4 and other multiple endocrine neoplasias due to cyclin-dependent kinase inhibitors (p27(Kip1) and p18(INK4C)) mutations.","date":"2010","source":"Best practice & research. Clinical endocrinology & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/20833334","citation_count":39,"is_preprint":false},{"pmid":"15349907","id":"PMC_15349907","title":"Reduced expression of cell cycle regulator p18(INK4C) in human hepatocellular carcinoma.","date":"2004","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/15349907","citation_count":39,"is_preprint":false},{"pmid":"9537438","id":"PMC_9537438","title":"Analysis of CDKN2A, CDKN2B, CDKN2C, and cyclin Ds gene status in hepatoblastoma.","date":"1998","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/9537438","citation_count":38,"is_preprint":false},{"pmid":"27610696","id":"PMC_27610696","title":"Role of CDKN2C Copy Number in Sporadic Medullary Thyroid Carcinoma.","date":"2016","source":"Thyroid : official journal of the American Thyroid Association","url":"https://pubmed.ncbi.nlm.nih.gov/27610696","citation_count":38,"is_preprint":false},{"pmid":"10517502","id":"PMC_10517502","title":"Homozygous deletions of the CDKN2C/p18INK4C gene on the short arm of chromosome 1 in anaplastic oligodendrogliomas.","date":"1999","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/10517502","citation_count":38,"is_preprint":false},{"pmid":"9724087","id":"PMC_9724087","title":"Screening of germline mutations in the CDK4, CDKN2C and TP53 genes in familial melanoma: a clinic-based population study.","date":"1998","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9724087","citation_count":36,"is_preprint":false},{"pmid":"18316595","id":"PMC_18316595","title":"Synergistic effect of oncogenic RET and loss of p18 on medullary thyroid carcinoma development.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18316595","citation_count":36,"is_preprint":false},{"pmid":"23781028","id":"PMC_23781028","title":"The lysosomal signaling anchor p18/LAMTOR1 controls epidermal development by regulating lysosome-mediated catabolic processes.","date":"2013","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/23781028","citation_count":36,"is_preprint":false},{"pmid":"18343821","id":"PMC_18343821","title":"Determination of three-dimensional structure and residues of the novel tumor suppressor AIMP3/p18 required for the interaction with ATM.","date":"2008","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18343821","citation_count":36,"is_preprint":false},{"pmid":"14681224","id":"PMC_14681224","title":"The p18 truncated form of Bax behaves like a Bcl-2 homology domain 3-only protein.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14681224","citation_count":36,"is_preprint":false},{"pmid":"10556039","id":"PMC_10556039","title":"Tumor suppressor INK4: comparisons of conformational properties between p16(INK4A) and p18(INK4C).","date":"1999","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10556039","citation_count":35,"is_preprint":false},{"pmid":"24377928","id":"PMC_24377928","title":"p18/LAMTOR1: a late endosome/lysosome-specific anchor protein for the mTORC1/MAPK signaling pathway.","date":"2014","source":"Methods in enzymology","url":"https://pubmed.ncbi.nlm.nih.gov/24377928","citation_count":35,"is_preprint":false},{"pmid":"16820479","id":"PMC_16820479","title":"A protective immune response is generated in rainbow trout by an OmpH-like surface antigen (P18) of Flavobacterium psychrophilum.","date":"2006","source":"Applied and environmental microbiology","url":"https://pubmed.ncbi.nlm.nih.gov/16820479","citation_count":35,"is_preprint":false},{"pmid":"22997239","id":"PMC_22997239","title":"Dual suppression of the cyclin-dependent kinase inhibitors CDKN2C and CDKN1A in human melanoma.","date":"2012","source":"Journal of the National Cancer Institute","url":"https://pubmed.ncbi.nlm.nih.gov/22997239","citation_count":33,"is_preprint":false},{"pmid":"2278968","id":"PMC_2278968","title":"A gene that encodes for a leukemia-associated phosphoprotein (p18) maps to chromosome bands 1p35-36.1.","date":"1990","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/2278968","citation_count":33,"is_preprint":false},{"pmid":"1939149","id":"PMC_1939149","title":"Regulated expression of p18, a major phosphoprotein of leukemic cells.","date":"1991","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1939149","citation_count":33,"is_preprint":false},{"pmid":"9286748","id":"PMC_9286748","title":"Parathyroid tumor suppressor on 1p: analysis of the p18 cyclin-dependent kinase inhibitor gene as a candidate.","date":"1997","source":"Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research","url":"https://pubmed.ncbi.nlm.nih.gov/9286748","citation_count":32,"is_preprint":false},{"pmid":"2456086","id":"PMC_2456086","title":"Monoclonal antibodies to the human immunodeficiency virus p18 protein cross-react with normal human tissues.","date":"1988","source":"AIDS (London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/2456086","citation_count":32,"is_preprint":false},{"pmid":"3667521","id":"PMC_3667521","title":"Bacterial metabolism of alpha-pinene: pathway from alpha-pinene oxide to acyclic metabolites in Nocardia sp. strain P18.3.","date":"1987","source":"Journal of bacteriology","url":"https://pubmed.ncbi.nlm.nih.gov/3667521","citation_count":32,"is_preprint":false},{"pmid":"29694893","id":"PMC_29694893","title":"SETDB2 Links E2A-PBX1 to Cell-Cycle Dysregulation in Acute Leukemia through CDKN2C Repression.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/29694893","citation_count":29,"is_preprint":false},{"pmid":"9432125","id":"PMC_9432125","title":"Structural and functional analysis of cyclin-dependent kinase inhibitor genes (CDKN2A, CDKN2B, and CDKN2C) in neuroblastoma.","date":"1998","source":"Pediatric research","url":"https://pubmed.ncbi.nlm.nih.gov/9432125","citation_count":29,"is_preprint":false},{"pmid":"19401813","id":"PMC_19401813","title":"Expression of p18(INK4C) is down-regulated in human pituitary adenomas.","date":"2009","source":"Endocrine pathology","url":"https://pubmed.ncbi.nlm.nih.gov/19401813","citation_count":28,"is_preprint":false},{"pmid":"24167278","id":"PMC_24167278","title":"Gata3/Ruvbl2 complex regulates T helper 2 cell proliferation via repression of Cdkn2c expression.","date":"2013","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/24167278","citation_count":28,"is_preprint":false},{"pmid":"32090490","id":"PMC_32090490","title":"miR-21-5p promotes cell proliferation and G1/S transition in melanoma by targeting CDKN2C.","date":"2020","source":"FEBS open bio","url":"https://pubmed.ncbi.nlm.nih.gov/32090490","citation_count":27,"is_preprint":false},{"pmid":"21543644","id":"PMC_21543644","title":"Cyclin-dependent kinase inhibitor Cdkn2c regulates B cell homeostasis and function in the NZM2410-derived murine lupus susceptibility locus Sle2c1.","date":"2011","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/21543644","citation_count":27,"is_preprint":false},{"pmid":"25404710","id":"PMC_25404710","title":"p18, a novel adaptor protein, regulates pulmonary endothelial barrier function via enhanced endocytic recycling of VE-cadherin.","date":"2014","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/25404710","citation_count":26,"is_preprint":false},{"pmid":"16953232","id":"PMC_16953232","title":"Simultaneous downregulation of CDK inhibitors p18(Ink4c) and p27(Kip1) is required for MEN2A-RET-mediated mitogenesis.","date":"2006","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/16953232","citation_count":25,"is_preprint":false},{"pmid":"24443788","id":"PMC_24443788","title":"High prevalence of Y-box protein-1/p18 fragment in plasma of patients with malignancies of different origin.","date":"2014","source":"BMC cancer","url":"https://pubmed.ncbi.nlm.nih.gov/24443788","citation_count":25,"is_preprint":false},{"pmid":"7688170","id":"PMC_7688170","title":"Envelope protein and p18(IIIB) peptide recognized by cytotoxic T lymphocytes from humans immunized with human immunodeficiency virus envelope.","date":"1993","source":"Vaccine","url":"https://pubmed.ncbi.nlm.nih.gov/7688170","citation_count":25,"is_preprint":false},{"pmid":"12821941","id":"PMC_12821941","title":"Suppression of ARG kinase activity by STI571 induces cell cycle arrest through up-regulation of CDK inhibitor p18/INK4c.","date":"2003","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/12821941","citation_count":25,"is_preprint":false},{"pmid":"11263500","id":"PMC_11263500","title":"Frequent loss of 1p32 region but no mutation of the p18 tumor suppressor gene in meningiomas.","date":"2000","source":"Journal of neuro-oncology","url":"https://pubmed.ncbi.nlm.nih.gov/11263500","citation_count":24,"is_preprint":false},{"pmid":"8665486","id":"PMC_8665486","title":"The p16 and p18 tumor suppressor genes in neuroblastoma: implications for drug resistance.","date":"1996","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/8665486","citation_count":24,"is_preprint":false},{"pmid":"17803708","id":"PMC_17803708","title":"Evaluation of CDKN2C/p18, CDKN1B/p27 and CDKN2B/p15 mRNA expression, and CpG methylation status in sporadic and MEN1-associated pancreatic endocrine tumours.","date":"2007","source":"Clinical endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/17803708","citation_count":24,"is_preprint":false},{"pmid":"23175770","id":"PMC_23175770","title":"Zebrafish dmrta2 regulates the expression of cdkn2c in spermatogenesis in the adult testis.","date":"2013","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/23175770","citation_count":23,"is_preprint":false},{"pmid":"17049078","id":"PMC_17049078","title":"Paradoxical expression of INK4c in proliferative multiple myeloma tumors: bi-allelic deletion vs increased expression.","date":"2006","source":"Cell division","url":"https://pubmed.ncbi.nlm.nih.gov/17049078","citation_count":23,"is_preprint":false},{"pmid":"32945431","id":"PMC_32945431","title":"PRMT6 serves an oncogenic role in lung adenocarcinoma via regulating p18.","date":"2020","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/32945431","citation_count":23,"is_preprint":false},{"pmid":"12668976","id":"PMC_12668976","title":"p18(INK4c) collaborates with other CDK-inhibitory proteins in the regenerating liver.","date":"2003","source":"Hepatology (Baltimore, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/12668976","citation_count":23,"is_preprint":false},{"pmid":"8519415","id":"PMC_8519415","title":"Molecular analysis of a family of cyclin-dependent kinase inhibitor genes (p15/MTS2/INK4b and p18/INK4c) in non-small cell lung cancers.","date":"1995","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/8519415","citation_count":23,"is_preprint":false},{"pmid":"22896639","id":"PMC_22896639","title":"Cyclin-dependent kinase inhibitor Cdkn2c deficiency promotes B1a cell expansion and autoimmunity in a mouse model of lupus.","date":"2012","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/22896639","citation_count":22,"is_preprint":false},{"pmid":"26985855","id":"PMC_26985855","title":"CDKIs p18(INK4c) and p57(Kip2) are involved in quiescence of CML leukemic stem cells after treatment with TKI.","date":"2016","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/26985855","citation_count":21,"is_preprint":false},{"pmid":"15584024","id":"PMC_15584024","title":"Tumorigenesis in p27/p53- and p18/p53-double null mice: functional collaboration between the pRb and p53 pathways.","date":"2005","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/15584024","citation_count":21,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":51363,"output_tokens":6998,"usd":0.129529},"stage2":{"model":"claude-opus-4-6","input_tokens":10742,"output_tokens":3975,"usd":0.229628},"total_usd":0.359157,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1994,\n      \"finding\": \"CDKN2C/p18(INK4c) directly binds CDK6 (strongly) and CDK4 (weakly) in vivo and in vitro, forms binary complexes (not ternary with cyclins), inhibits cyclin D-CDK6 kinase activity, and suppresses cell growth in a pRb-dependent manner.\",\n      \"method\": \"Yeast two-hybrid screen, co-immunoprecipitation, in vitro kinase assay, ectopic expression with growth suppression assay\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro kinase assay + Co-IP + functional growth suppression, replicated across multiple labs\",\n      \"pmids\": [\"8001816\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Mouse p18(INK4c) specifically inhibits CDK4 and CDK6 kinase activities but not cyclin E-CDK2, cyclin A-CDK2, or cyclin B-CDC2; it binds CDK4/6 whether free or in cyclin D complexes, displaces cyclins from CDKs in vivo (forming binary inhibitor-CDK complexes), and ectopic expression causes G1 arrest.\",\n      \"method\": \"In vitro kinase assays, co-immunoprecipitation, ectopic expression with FACS cell cycle analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro reconstitution + in vivo complex analysis + G1 arrest phenotype, replicated\",\n      \"pmids\": [\"7739547\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"In terminally differentiating B cells, IL-6 activates p18(INK4c) expression, markedly enhances its association with CDK6, suppresses pRb phosphorylation, and causes cell cycle arrest; overexpression of p18 in IgM-bearing lymphoblastoid cells reconstitutes coupled differentiation and cell cycle arrest.\",\n      \"method\": \"Co-immunoprecipitation, Western blot, ectopic overexpression, flow cytometry\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP + overexpression rescue + defined cellular phenotype\",\n      \"pmids\": [\"9052836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"p18(INK4c)-deficient mice develop gigantism, organomegaly, pituitary hyperplasia progressing to adenoma; combined loss of p18 and p27 (two distinct CDK inhibitor pathways) leads to invariable pituitary adenoma death by 3 months, demonstrating that p18 and p27 suppress pituitary tumorigenesis via separate pathways converging on Rb.\",\n      \"method\": \"Gene targeting (knockout mice), histopathology, epistasis with p27 double knockout\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined phenotype + genetic epistasis replicated in multiple genotypes\",\n      \"pmids\": [\"9744866\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"NMR and H/D exchange analyses show that p18(INK4c) is more kinetically stable than p16(INK4A) and p15(INK4B), with slowly exchanging residues concentrated in the fourth ankyrin repeat, conferring distinct conformational flexibility on the microsecond–hour timescale.\",\n      \"method\": \"NMR (heteronuclear NOE, H/D exchange), chemical denaturation\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — NMR structural characterization with functional stability comparison\",\n      \"pmids\": [\"10556039\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"During adipogenesis, PPARγ directly induces p18(INK4c) expression at the onset of terminal differentiation, coordinating irreversible G1 arrest; ectopic PPARγ in non-precursor fibroblasts induces p18 mRNA and protein in a ligand-dependent manner.\",\n      \"method\": \"Stable cell lines with ectopic PPARγ, Western blot, Northern blot, PPARγ ligand treatment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ectopic transcription factor expression with defined p18 induction and differentiation phenotype\",\n      \"pmids\": [\"10358062\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Ablation of p18(INK4c) alone or combined with p15(INK4b) causes lymphoproliferative disorders and renal/mammary epithelial cysts in mice; p15 but not p18 loss confers proliferative advantage to MEFs and sensitizes them to H-ras transformation, indicating non-redundant tumor suppressor roles in different lineages.\",\n      \"method\": \"Gene targeting (single and double knockout mice), MEF transformation assays, histopathology\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined phenotype + double KO epistasis\",\n      \"pmids\": [\"10880462\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Progestin treatment of T-47D breast cancer cells increases p18(INK4c) expression and promotes its extensive association with CDK4 and CDK6; recombinant p18(INK4c) in vitro reassorts cyclin-CDK-inhibitor complexes, indirectly reducing cyclin E-CDK2 activity, demonstrating cooperation with p27(Kip1) in G1 arrest.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay with recombinant p18, Western blot, gel filtration\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro reconstitution + in vivo Co-IP with defined functional consequence\",\n      \"pmids\": [\"10713180\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"p18(INK4c) is required for B cell terminal differentiation into functional plasma cells: p18-null B cells hyperproliferate in germinal centers and extrafollicular foci but produce severely reduced antibody titers, linking p18-mediated CDK6 inhibition to cell cycle exit required for plasma cell function.\",\n      \"method\": \"Knockout mice, B cell immunization assays, antibody titer measurement, histology\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined cellular and immunological phenotype\",\n      \"pmids\": [\"12196289\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"p18(INK4c) selectively associates with and inhibits CDK6 (not CDK4) in activated T cells; p18-null T cells hyperproliferate in response to CD3 stimulation, and p18 sets an inhibitory threshold on TCR-mediated proliferation via CDK6.\",\n      \"method\": \"Knockout mice, co-immunoprecipitation, T cell proliferation assays, flow cytometry\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — KO phenotype + selective Co-IP with CDK6\",\n      \"pmids\": [\"11544316\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Combined loss of Ink4c and Ink4d in mice causes male infertility through delayed spermatogonial exit from mitosis, aberrant meiosis, spermatocyte apoptosis, and Leydig cell hyperplasia with reduced testosterone; Ink4c single loss causes Leydig cell hyperplasia independently of Ink4d.\",\n      \"method\": \"Single and double knockout mice, histopathology, hormone measurements, cell cycle analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean double KO with defined spermatogenesis and endocrine phenotype\",\n      \"pmids\": [\"11287627\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"p18(INK4c) is overexpressed in multiple myeloma (MM) cell lines with p16 co-deletion; zinc-inducible ectopic p18 expression in p18-deficient MM cells causes 40–45% growth suppression and induces apoptosis, demonstrating that p18 inhibits the cyclin D1/CDK/pRb pathway in myeloma.\",\n      \"method\": \"Inducible expression system, trypan blue exclusion, MTS assay, apoptosis assay\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean inducible OE with defined apoptosis and growth phenotype, single lab\",\n      \"pmids\": [\"11840272\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Posttranscriptional upregulation of p18(INK4c) protein during oligodendrocyte precursor cell (OPC) proliferation contributes to a cell-intrinsic differentiation timer; overexpression of p18 in OPCs accelerates premature differentiation.\",\n      \"method\": \"Overexpression in primary OPC cultures, cell cycle analysis, differentiation assay\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — overexpression phenotype in primary cells, single lab\",\n      \"pmids\": [\"11969268\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Haploinsufficiency of p18(INK4c) in mice sensitizes to carcinogen-induced tumorigenesis; the remaining wild-type allele is neither mutated nor silenced in heterozygote tumors, establishing p18 as a haploinsufficient tumor suppressor.\",\n      \"method\": \"Chemical carcinogenesis in p18+/- and p18-/- mice, LOH analysis, sequencing\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic model with molecular verification of haploinsufficiency\",\n      \"pmids\": [\"12556487\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Ink4c (p18) collaborates with p53 independently of Patched to suppress medulloblastoma: Ink4c haploinsufficiency combined with Ptc1 heterozygosity causes rapid medulloblastoma with loss of the wild-type Ptc1 allele (not Ink4c), showing Ink4c haploinsufficiency for tumor suppression in this context.\",\n      \"method\": \"Mouse genetics (compound heterozygous/null crosses), LOH analysis, GNP cell proliferation assays, in situ hybridization\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in vivo + LOH molecular analysis + cell culture phenotype\",\n      \"pmids\": [\"16260494\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Deletion of p18(INK4c) in hematopoietic stem cells (HSCs) results in improved long-term engraftment and increased self-renewing divisions; p18 absence significantly decelerates hematopoietic exhaustion caused by p21 deficiency, demonstrating opposing roles of p18 (restricts self-renewal) and p21 (limits exhaustion) at the HSC level.\",\n      \"method\": \"Serial bone marrow transplantation, single KO and double KO mice, competitive repopulation assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO with defined HSC functional phenotype across multiple transplant generations\",\n      \"pmids\": [\"16234365\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"p18(INK4c) cooperates with p27(Kip1) to suppress MEN-like pituitary and thyroid tumorigenesis; oncogenic RET2A represses p18 mRNA levels via MAPK signaling, reduces p18 protein, elevates cyclin D1, increases CDK activity and pRb phosphorylation, and p18 downregulation is required and sufficient for RET2A-mediated mitogenesis.\",\n      \"method\": \"Inducible RET2A expression, RT-PCR, Western blot, kinase assay, antisense knockdown, double KO mice\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (knockdown, KO mice, kinase assay) in single lab\",\n      \"pmids\": [\"16953232\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"p18 Ink4c and Pten cooperate to suppress tumorigenesis via a positive feedback loop between cell growth (PI3K/Akt/mTOR) and cell cycle control; p18 deletion, CDK4 overexpression, or viral Rb inactivation each cause Akt activation, suggesting the CDK4-Rb pathway feeds back to regulate Akt.\",\n      \"method\": \"Double mutant mice (p18/Pten), Western blot for Akt activation, tumor incidence analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in vivo + biochemical readout, single lab\",\n      \"pmids\": [\"16738322\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Crystal structure of AIMP3/p18 (a component of the multi-tRNA synthetase complex, also known as p18 tumor suppressor) determined at 2.0 Å; structure reveals two distinct domains; mutations at the C-terminal domain abolish interaction with ATM and p53 activation, identifying residues critical for tumor-suppressive activity.\",\n      \"method\": \"X-ray crystallography, mutagenesis, co-immunoprecipitation, p53 activation assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — crystal structure + mutagenesis + functional validation in single study\",\n      \"pmids\": [\"18343821\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Somatic mutations in CDKN2C/p18(INK4c) found in human RET-associated medullary thyroid carcinoma and pheochromocytoma cause amino acid substitutions in the CDK-interacting region, partially inhibit p18 function and reduce its stability, implicating p18 as a tumor suppressor in these cancers.\",\n      \"method\": \"Mutation sequencing of patient tumors, in vitro functional assays of mutant p18\",\n      \"journal\": \"International journal of cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — somatic mutations + in vitro functional characterization, single lab\",\n      \"pmids\": [\"18942719\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Lentiviral reconstitution of p18(INK4c) expression at physiological levels in p18-deficient GBM cells induces senescence-like G1 arrest; p18-proficient GBM cells are unaffected, identifying p18 loss as a driver of CDK dysregulation in glioblastoma.\",\n      \"method\": \"Lentiviral gene reconstitution, flow cytometry (cell cycle), immunohistochemistry\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — clean reconstitution experiment with defined G1 arrest phenotype, single lab\",\n      \"pmids\": [\"18381405\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"GATA3 directly binds the INK4C/CDKN2C promoter and represses its transcription, placing p18(INK4c) downstream of GATA3 in luminal mammary progenitor cells; p18-null mice spontaneously develop ER-positive luminal tumors with expanded luminal progenitor populations.\",\n      \"method\": \"ChIP, luciferase reporter assay, knockout mice, tumor histopathology, gene expression profiling\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — ChIP + reporter assay + KO phenotype, multiple orthogonal methods\",\n      \"pmids\": [\"19411068\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"AIMP3/p18 overexpression causes proteasome-dependent degradation of mature lamin A (not lamin C, prelamin A, or progerin), leading to altered lamin A isoform stoichiometry, accelerated cellular senescence, nuclear morphology defects, and a progeroid phenotype in transgenic mice.\",\n      \"method\": \"Transgenic mice, Western blot, proteasome inhibitor treatment, cell morphology assay\",\n      \"journal\": \"Aging cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — transgenic OE + proteasome inhibitor rescue + defined phenotype, single lab\",\n      \"pmids\": [\"20726853\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Cdkn2c/p18 deficiency in C57BL/6 mice causes dose-dependent expansion of peritoneal B1a cells (but not splenic conventional B cells) with enhanced homeostatic B1a proliferation; elevated B1a numbers are normalized by cyclin D2 deficiency, placing p18 upstream of cyclin D2 in B1a cell pool regulation.\",\n      \"method\": \"Knockout mice, flow cytometry, cyclin D2 double KO epistasis, autoantibody measurement\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean KO + epistasis with cyclin D2 + defined cellular phenotype\",\n      \"pmids\": [\"22896639\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"MAPK/BRAF(V600E) signaling promotes melanoma G1 cell cycle progression via AP-1-mediated transcriptional repression of CDKN2C; dominant-negative AP-1 de-represses CDKN2C, and CDK4 inhibition antagonizes BRAF(V600E) proliferative effects.\",\n      \"method\": \"Dominant-negative AP-1, cell proliferation assay, Western blot, flow cytometry, in vivo xenograft\",\n      \"journal\": \"Journal of the National Cancer Institute\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — dominant-negative + pharmacological inhibition + in vivo validation, single lab\",\n      \"pmids\": [\"22997239\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"GATA3 associates with RuvBL2 (Ruvbl2) to form a complex that directly binds the Cdkn2c locus and represses Cdkn2c expression in Th2 cells; knockdown of Cdkn2c rescues the proliferation defect of Gata3-deficient Th2 cells, establishing Cdkn2c as a key mediator of Gata3-driven Th2 cell proliferation.\",\n      \"method\": \"ChIP, co-immunoprecipitation, siRNA knockdown, in vitro proliferation assay, in vivo airway inflammation model\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — ChIP + Co-IP + knockdown rescue, multiple orthogonal methods\",\n      \"pmids\": [\"24167278\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Small-molecule inhibitors identified by structure-based in silico screening against p18(INK4c) specifically block p18 activity and expand functional HSCs in short-term culture, demonstrating that pharmacological inhibition of p18's CDK-inhibitory function promotes HSC self-renewing division.\",\n      \"method\": \"In silico screening based on p18 protein structure, in vitro kinase inhibition assay, single-cell HSC culture, transplantation assay\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — structure-guided inhibitor design + functional HSC expansion assay, single lab\",\n      \"pmids\": [\"25692908\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SETDB2 (protein lysine methyltransferase) suppresses CDKN2C expression via histone H3K9 tri-methylation at the CDKN2C locus downstream of the E2A-PBX1 chimeric transcription factor in pre-BCR+ ALL, establishing an oncogenic pathway that silences CDKN2C as a major tumor suppressor.\",\n      \"method\": \"ChIP, SETDB2 knockdown, gene expression analysis, in vitro and in vivo leukemia maintenance assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP + KD with defined phenotype + epistatic pathway placement\",\n      \"pmids\": [\"29694893\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"miR-21-5p directly targets CDKN2C 3'UTR (validated by luciferase reporter assay), decreases CDKN2C protein levels, and promotes G1/S transition and proliferation in melanoma cells; CDKN2C overexpression partially reverses miR-21-5p-driven proliferation.\",\n      \"method\": \"Luciferase reporter assay, miRNA mimic/inhibitor, Western blot, flow cytometry, rescue experiment\",\n      \"journal\": \"FEBS open bio\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct 3'UTR reporter validation + rescue experiment, single lab\",\n      \"pmids\": [\"32090490\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PRMT6 epigenetically suppresses CDKN2C/p18 expression via asymmetric dimethylation of histone H3R2 at the p18 promoter; PRMT6 knockdown reduces H3R2me2a enrichment at the p18 promoter, activates p18 expression, induces G1/S arrest, and inhibits lung adenocarcinoma cell proliferation in vitro and in vivo.\",\n      \"method\": \"ChIP assay, PRMT6 siRNA knockdown, Western blot, cell cycle analysis, xenograft model\",\n      \"journal\": \"Molecular medicine reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — ChIP + KD + in vivo validation, single lab\",\n      \"pmids\": [\"32945431\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"p18(INK4c) and p16(INK4A) each form 1:1 binary complexes with CDK4/CDK6 (no free kinase detectable); p16 can dissociate preformed CDK4-cyclin D1 complexes in vitro, demonstrating competitive displacement of cyclin by INK4 inhibitors.\",\n      \"method\": \"In vitro dissociation assay with purified proteins, co-immunoprecipitation, Western blot\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution demonstrating competitive displacement with purified components\",\n      \"pmids\": [\"8663131\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"miR-543 and miR-590-3p directly bind AIMP3/p18 transcripts and decrease AIMP3/p18 expression; their levels decline under senescence-inducing conditions in human MSCs, allowing AIMP3/p18 upregulation which induces senescence phenotypes including impaired clonogenicity and adipogenic differentiation.\",\n      \"method\": \"miRNA mimic/inhibitor transfection, luciferase reporter assay (direct binding), Western blot, senescence assays\",\n      \"journal\": \"Age (Dordrecht, Netherlands)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding validated by reporter + loss-of-function phenotype, single lab\",\n      \"pmids\": [\"25465621\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CDKN2C/p18(INK4c) is a CDK inhibitor that forms binary complexes with CDK4 and CDK6 (preferentially CDK6), competitively displacing D-type cyclins to block G1-phase kinase activity and pRb phosphorylation, thereby restraining cell cycle entry; its expression is transcriptionally repressed by GATA3/RuvBL2 and AP-1 downstream of BRAF(V600E)/MAPK signaling, epigenetically silenced by SETDB2 (H3K9me3) and PRMT6 (H3R2me2a), and post-transcriptionally regulated by miR-21-5p and miR-543/590-3p, while loss of p18 collaborates with loss of p27 and inactivation of p53 or Pten to promote tissue-specific tumorigenesis (pituitary, mammary, thyroid, hematopoietic), and p18 also restricts hematopoietic stem cell self-renewal and controls terminal differentiation in B cells, T cells, and spermatocytes.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CDKN2C/p18(INK4c) is a CDK inhibitor that restrains G1-phase cell cycle progression by forming binary complexes with CDK4 and especially CDK6, competitively displacing D-type cyclins to block pRb phosphorylation and enforce cell cycle exit during terminal differentiation in B cells, T cells, adipocytes, oligodendrocyte precursors, and spermatocytes [PMID:8001816, PMID:7739547, PMID:9052836, PMID:10358062]. p18 functions as a haploinsufficient tumor suppressor whose loss cooperates with deficiency of p27(Kip1), p53, or Pten to drive pituitary, thyroid, mammary, and hematopoietic tumors in mice, and whose expression is transcriptionally repressed by GATA3/RuvBL2, AP-1 downstream of BRAF(V600E)/MAPK signaling, and epigenetically silenced by SETDB2-mediated H3K9me3 and PRMT6-mediated H3R2me2a [PMID:9744866, PMID:12556487, PMID:19411068, PMID:29694893, PMID:32945431]. In the hematopoietic stem cell compartment, p18 restricts self-renewal such that its genetic or pharmacological inhibition expands functional HSCs [PMID:16234365, PMID:25692908]. Somatic loss-of-function mutations in CDKN2C occur in RET-associated medullary thyroid carcinoma and pheochromocytoma, and CDKN2C silencing contributes to glioblastoma and melanoma progression [PMID:18942719, PMID:18381405, PMID:22997239].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Identification of p18(INK4c) as a CDK6/CDK4-specific inhibitor that forms binary (not ternary) complexes and suppresses growth in a pRb-dependent manner established the founding biochemical mechanism of this INK4 family member.\",\n      \"evidence\": \"Yeast two-hybrid, co-immunoprecipitation, in vitro kinase assays, and ectopic expression growth suppression in human cells\",\n      \"pmids\": [\"8001816\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for CDK6 preference over CDK4 not resolved\", \"Endogenous physiological context of p18 action unknown\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"Demonstration that p18 specifically inhibits CDK4/6 but not CDK2 or CDC2, and displaces cyclins from preformed complexes in vivo, clarified the competitive displacement mechanism and CDK selectivity of INK4c.\",\n      \"evidence\": \"In vitro kinase assays across multiple CDK-cyclin pairs, co-immunoprecipitation of endogenous complexes, FACS cell cycle analysis in mouse cells\",\n      \"pmids\": [\"7739547\", \"8663131\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative binding affinities for CDK4 vs CDK6 not determined\", \"Whether cyclin displacement is kinetically reversible in vivo unknown\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Discovery that IL-6 induces p18 during B cell terminal differentiation, coupling CDK6 inhibition to cell cycle exit and immunoglobulin secretion, provided the first physiological differentiation context for p18.\",\n      \"evidence\": \"Co-immunoprecipitation showing enhanced p18-CDK6 association, overexpression reconstituting coupled differentiation and arrest in lymphoblastoid cells\",\n      \"pmids\": [\"9052836\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Transcriptional vs post-transcriptional regulation by IL-6 not dissected\", \"Whether p18 is required (vs sufficient) for plasma cell differentiation not tested\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Knockout mouse studies established p18 as a bona fide tumor suppressor whose loss causes pituitary hyperplasia/adenoma and cooperates with p27 loss through independent pathways converging on Rb, defining the in vivo tumor suppressor function.\",\n      \"evidence\": \"Gene targeting in mice with single and double (p18/p27) knockouts, histopathology, epistasis analysis\",\n      \"pmids\": [\"9744866\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell-autonomous vs systemic (e.g. hormonal) contribution to pituitary tumorigenesis not separated\", \"Human pituitary tumor relevance not established\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"NMR structural analysis revealed that p18 has greater kinetic stability than p16 and p15, with the fourth ankyrin repeat as the stability core, providing a biophysical basis for differential INK4 family behavior.\",\n      \"evidence\": \"NMR heteronuclear NOE and H/D exchange measurements, chemical denaturation comparison\",\n      \"pmids\": [\"10556039\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No co-crystal structure with CDK6 to map the binding interface\", \"Functional consequence of enhanced stability not tested in cells\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Identification of PPARγ as a direct transcriptional activator of p18 during adipogenesis linked p18 induction to the irreversible cell cycle exit accompanying terminal differentiation in a non-hematopoietic lineage.\",\n      \"evidence\": \"Ectopic PPARγ expression in fibroblasts with ligand-dependent p18 mRNA/protein induction\",\n      \"pmids\": [\"10358062\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct promoter binding by PPARγ not shown by ChIP\", \"Whether p18 is necessary for adipocyte cell cycle exit not tested by loss-of-function\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Studies in breast cancer cells showed that progestin-induced p18 upregulation reassorts CDK-cyclin-inhibitor complexes to indirectly suppress cyclin E-CDK2 activity through cooperation with p27, revealing a two-step CDK inhibition cascade linking INK4 and Cip/Kip families.\",\n      \"evidence\": \"Co-immunoprecipitation, in vitro reconstitution with recombinant p18, gel filtration of endogenous complexes\",\n      \"pmids\": [\"10713180\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometric requirements for complex reassortment not quantified\", \"In vivo relevance of progestin-p18 axis in mammary tumor suppression not tested\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Functional studies in knockout mice extended p18's differentiation roles to T cells (CDK6-selective threshold on TCR proliferation), B cell plasma cell differentiation (required for antibody production), and spermatogenesis (cooperation with p19/INK4d for meiotic progression), demonstrating broad lineage-specific functions.\",\n      \"evidence\": \"Single and double knockout mice with immunization, proliferation assays, histopathology, and hormone measurements\",\n      \"pmids\": [\"11544316\", \"12196289\", \"11287627\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CDK6 selectivity in T cells reflects expression patterns or intrinsic affinity not resolved\", \"Molecular mechanism linking p18 loss to meiotic defects unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstration that p18 is haploinsufficient for tumor suppression — heterozygous mice develop carcinogen-induced tumors without loss or silencing of the remaining allele — established a dosage-sensitive mode of tumor suppression distinct from classical two-hit models.\",\n      \"evidence\": \"Chemical carcinogenesis in p18+/- mice with LOH analysis and sequencing of remaining allele\",\n      \"pmids\": [\"12556487\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether haploinsufficiency operates in human cancers not tested\", \"Threshold level of p18 protein required for tumor suppression unknown\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Discovery that p18 restricts hematopoietic stem cell self-renewal, with p18 loss improving long-term engraftment and opposing the exhaustion phenotype of p21 deficiency, positioned p18 as a stem cell quiescence regulator distinct from proliferation arrest.\",\n      \"evidence\": \"Serial competitive bone marrow transplantation in single and double knockout mice\",\n      \"pmids\": [\"16234365\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether p18 acts cell-autonomously in HSCs vs through niche effects not fully resolved\", \"CDK4 vs CDK6 target in HSCs not determined\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Genetic epistasis between p18/Pten and p18/p27 in thyroid and pituitary tumorigenesis revealed crosstalk between CDK4-Rb and PI3K/Akt/mTOR pathways, with p18 deletion activating Akt, suggesting a feedback loop from cell cycle control to growth signaling.\",\n      \"evidence\": \"Compound mutant mice, Western blot for Akt phosphorylation, tumor incidence and histopathology\",\n      \"pmids\": [\"16738322\", \"16953232\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of CDK4-Rb to Akt feedback not molecularly defined\", \"Whether feedback operates in human tumors unknown\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"ChIP and reporter assays showed GATA3 directly binds and represses the CDKN2C promoter in mammary and Th2 cells (via a RuvBL2-containing complex), and p18-null mice develop ER-positive luminal tumors, establishing a GATA3→p18 transcriptional axis controlling luminal progenitor expansion.\",\n      \"evidence\": \"ChIP, luciferase reporter, co-immunoprecipitation of GATA3-RuvBL2, knockout mice with tumor histopathology, siRNA rescue\",\n      \"pmids\": [\"19411068\", \"24167278\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether GATA3 mutations in human breast cancer act through p18 derepression not tested\", \"Genomic occupancy of GATA3-RuvBL2 at CDKN2C not mapped at nucleotide resolution\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Identification of AP-1-mediated CDKN2C transcriptional repression downstream of BRAF(V600E)/MAPK signaling in melanoma explained how oncogenic MAPK activity overrides the p18-CDK4/6-Rb checkpoint.\",\n      \"evidence\": \"Dominant-negative AP-1 derepresses CDKN2C, CDK4 inhibitor blocks BRAF(V600E) proliferative effects in vitro and xenograft\",\n      \"pmids\": [\"22997239\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct AP-1 binding to CDKN2C promoter not confirmed by ChIP\", \"Relative contribution of p18 vs p16 repression in melanoma not quantified\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Structure-based small-molecule inhibitors of p18 expanded functional HSCs in culture and transplantation, providing pharmacological proof-of-concept that p18's CDK-inhibitory activity can be therapeutically targeted to enhance stem cell self-renewal.\",\n      \"evidence\": \"In silico screening against p18 structure, in vitro kinase assay, single-cell HSC culture, transplantation\",\n      \"pmids\": [\"25692908\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Selectivity of inhibitors for p18 over other INK4 members not fully characterized\", \"Long-term safety of p18 inhibition in vivo not assessed\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Discovery that SETDB2 deposits H3K9me3 at the CDKN2C locus downstream of the E2A-PBX1 oncofusion to silence p18 in pre-B ALL established an epigenetic silencing axis as a tumor maintenance mechanism.\",\n      \"evidence\": \"ChIP for H3K9me3, SETDB2 knockdown restoring CDKN2C expression, in vivo leukemia maintenance assay\",\n      \"pmids\": [\"29694893\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether H3K9me3-based silencing is reversible with epigenetic drugs not tested\", \"Other SETDB2 targets that may contribute to leukemia maintenance not excluded\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Identification of miR-21-5p and PRMT6 (H3R2me2a) as additional negative regulators of CDKN2C in melanoma and lung adenocarcinoma, respectively, expanded the repertoire of post-transcriptional and epigenetic mechanisms that silence p18 in cancer.\",\n      \"evidence\": \"Luciferase 3'UTR reporter for miR-21-5p, ChIP for H3R2me2a at p18 promoter with PRMT6 knockdown, xenograft validation\",\n      \"pmids\": [\"32090490\", \"32945431\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Relative quantitative contribution of each silencing mechanism in individual tumors unknown\", \"Whether PRMT6 and SETDB2 act on the same or distinct chromatin states at CDKN2C not determined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the high-resolution structural basis for p18's strong CDK6 preference over CDK4, whether the CDK4-Rb-to-Akt feedback loop is a general mechanism in human cancers, and the therapeutic window for pharmacological p18 inhibition in stem cell expansion without tumor risk.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No co-crystal structure of p18-CDK6 complex available\", \"Mechanism of CDK4-Rb to Akt feedback not molecularly defined\", \"Long-term oncogenic risk of p18 inhibition in HSC expansion not assessed\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [0, 1, 7, 30]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [20, 29]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [0, 1, 7, 30]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [3, 13, 14, 19, 27]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [16, 17, 24]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [5, 8, 10, 12]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"CDK6\",\n      \"CDK4\",\n      \"GATA3\",\n      \"RUVBL2\",\n      \"SETDB2\",\n      \"PRMT6\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}